Manila Times Business
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Advancing CNTY-813 as a potential functional cure in Type 1 DiabetesCNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical modelsAllo-Evasion™ 5.0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppressionPhase 1 clinical manufacturing process has been established demonstrating consistent endocrine purity and optimal islet ce
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ocean Capital Acquisition Corporation Prices $100 Million Initial Public Offering
Just now
Fireaway Achieves Type Approval and EU/UK Marine Equipment Certification for Stat-X® Condensed Aerosol Fire-Extinguishing Systems Following MSC.1/Circ.1270 Evaluation
Just now
‘Habagat,’ localized thunderstorms bring scattered, isolated rains over PH
Just now
Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
1h ago